Emmaus Life Sciences Grants NeoImmuneTech Exclusive North American Rights to Endari

Reuters

Dec 31, 2025

<a href="https://laohu8.com/S/EMMA">Emmaus Life</a> Sciences Grants NeoImmuneTech Exclusive <a href="https://laohu8.com/S/FNCSF">North American</a> Rights to Endari

Emmaus Life Sciences Inc. announced that it has entered into a License and Exclusive Distribution Agreement with NeoImmuneTech, Inc. Under the terms of the agreement, Emmaus has granted NeoImmuneTech exclusive rights to market, sell, and distribute Endari® (prescription grade L-glutamine oral powder) and any generic equivalents for the treatment of sickle cell disease in the U.S., its territories, and Canada. The agreement includes an upfront payment to Emmaus and a royalty on product sales by NeoImmuneTech. The effective date of the agreement is contingent upon NeoImmuneTech obtaining the necessary regulatory approvals and licensing to sell and distribute the products, as well as the fulfillment of other specified conditions.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Emmaus Life Sciences Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20251230947552) on December 30, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2595471036"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2595471036\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2595471036?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-31 05:30","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2595471036","market":"us","top_or_hot":-1,"title":"Emmaus Life Sciences Grants NeoImmuneTech Exclusive North American Rights to Endari","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/EMMA\">Emmaus Life</a> Sciences Grants NeoImmuneTech Exclusive <a href=\"https://laohu8.com/S/FNCSF\">North American</a> Rights to Endari\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/EMMAW\">Emmaus Life</a> Sciences Inc. announced that it has entered into a License and Exclusive Distribution Agreement with NeoImmuneTech, Inc. Under the terms of the agreement, Emmaus has granted NeoImmuneTech exclusive rights to market, sell, and distribute Endari® (prescription grade L-glutamine oral powder) and any generic equivalents for the treatment of sickle cell disease in the U.S., its territories, and Canada. The agreement includes an upfront payment to Emmaus and a royalty on product sales by NeoImmuneTech. The effective date of the agreement is contingent upon NeoImmuneTech obtaining the necessary regulatory approvals and licensing to sell and distribute the products, as well as the fulfillment of other specified conditions.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Emmaus Life Sciences Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20251230947552) on December 30, 2025, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Emmaus Life Sciences Grants NeoImmuneTech Exclusive North American Rights to Endari</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nEmmaus Life Sciences Grants NeoImmuneTech Exclusive North American Rights to Endari\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-12-31 05:30</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/EMMA\">Emmaus Life</a> Sciences Grants NeoImmuneTech Exclusive <a href=\"https://laohu8.com/S/FNCSF\">North American</a> Rights to Endari\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/EMMAW\">Emmaus Life</a> Sciences Inc. announced that it has entered into a License and Exclusive Distribution Agreement with NeoImmuneTech, Inc. Under the terms of the agreement, Emmaus has granted NeoImmuneTech exclusive rights to market, sell, and distribute Endari® (prescription grade L-glutamine oral powder) and any generic equivalents for the treatment of sickle cell disease in the U.S., its territories, and Canada. The agreement includes an upfront payment to Emmaus and a royalty on product sales by NeoImmuneTech. The effective date of the agreement is contingent upon NeoImmuneTech obtaining the necessary regulatory approvals and licensing to sell and distribute the products, as well as the fulfillment of other specified conditions.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Emmaus Life Sciences Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20251230947552) on December 30, 2025, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4007","symbol_name":"制药","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251230:nNDL3ynWqd:1","article_id":"2595471036","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2595471036","pubTimestamp":1767130216,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Emmaus Life Sciences Inc. announced that it has entered into a License and Exclusive Distribution Agreement with NeoImmuneTech, Inc. Under the terms of the agreement, Emmaus has granted NeoImmuneTech exclusive rights to market, sell, and distribute Endari  and any generic equivalents for the treatment of sickle cell disease in the U.S., its territories, and Canada. The agreement includes an upfront payment to Emmaus and a royalty on product sales by NeoImmuneTech. The effective date of the agreement is contingent upon NeoImmuneTech obtaining the necessary regulatory approvals and licensing to sell and distribute the products, as well as the fulfillment of other specified conditions.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Emmaus","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4007":"制药","EMMA":"Emmaus生命科学"},"translate_title":"Emmaus Life Sciences授予NeoImmuneTech Endari北美独家权利","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"EMMA":0.9},"content_text":"Emmaus Life Sciences Grants NeoImmuneTech Exclusive North American Rights to Endari\n    \n\nEmmaus Life Sciences Inc. announced that it has entered into a License and Exclusive Distribution Agreement with NeoImmuneTech, Inc. Under the terms of the agreement, Emmaus has granted NeoImmuneTech exclusive rights to market, sell, and distribute Endari® (prescription grade L-glutamine oral powder) and any generic equivalents for the treatment of sickle cell disease in the U.S., its territories, and Canada. The agreement includes an upfront payment to Emmaus and a royalty on product sales by NeoImmuneTech. The effective date of the agreement is contingent upon NeoImmuneTech obtaining the necessary regulatory approvals and licensing to sell and distribute the products, as well as the fulfillment of other specified conditions.\n      \n\n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Emmaus Life Sciences Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20251230947552) on December 30, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}